Pinheiro Ronald Feitosa, Goes João Vitor Caetano, Sampaio Leticia Rodrigues, Germano de Oliveira Roberta Taiane, Lima Sheila Coelho Soares, Furtado Cristiana Libardi Miranda, de Paula Borges Daniela, Costa Marilia Braga, da Silva Monte Cristiane, Minete Natalia Feitosa, Magalhães Silvia Maria Meira, Ribeiro Junior Howard Lopes
Cancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza, Ceara, Brazil; Post-Graduate Program in Medical Science, Federal University of Ceara, Fortaleza, Ceara, Brazil; Post-Graduate Program of Pathology, Federal University of Ceara, Fortaleza, Ceara, Fortaleza, Ceara, Brazil.
Cancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza, Ceara, Brazil; Post-Graduate Program of Pathology, Federal University of Ceara, Fortaleza, Ceara, Fortaleza, Ceara, Brazil.
DNA Repair (Amst). 2025 Feb;146:103803. doi: 10.1016/j.dnarep.2024.103803. Epub 2025 Jan 17.
Myelodysplastic Neoplasm (MDS) is a cancer associated with aging, often leading to acute myeloid leukemia (AML). One of its hallmarks is hypermethylation, particularly in genes responsible for DNA repair. This study aimed to evaluate the methylation and mutation status of DNA repair genes (single-strand - XPA, XPC, XPG, CSA, CSB and double-strand - ATM, BRCA1, BRCA2, LIG4, RAD51) in MDS across three patient cohorts (Cohort A-56, Cohort B-100, Cohort C-76), using methods like pyrosequencing, real-time PCR, immunohistochemistry, and mutation screening. Results showed that XPA had higher methylation in low-risk MDS compared to high-risk MDS. For double-strand repair genes, ATM displayed higher methylation in patients who transformed to AML (p = 0.016). ATM gene expression was downregulated in MDS compared to controls (p = 0.042). When patients were classified according to the WHO 2022 guidelines, ATM expression progressively decreased from low-risk subtypes (e.g., Hypoplastic MDS) to high-risk MDS and AML. Patients who transformed to AML had a higher 5mC/5hmC ratio compared to those who didn't (p = 0.045). Additionally, poor cytogenetic risk patients had higher tissue methylation scores than those with good risk (p = 0.035). Analysis using the cBioPortal platform identified ATM as the most frequently mutated DNA repair gene, with various mutations, such as frameshift and missense, most of which were classified as oncogenic. The findings suggest that ATM is frequently silenced or downregulated in MDS due to methylation or mutations, contributing to the progression to AML. This highlights ATM's potential role in the disease's advancement and as a target for future therapeutic strategies.
骨髓增生异常综合征(MDS)是一种与衰老相关的癌症,常发展为急性髓系白血病(AML)。其特征之一是高甲基化,尤其是在负责DNA修复的基因中。本研究旨在通过焦磷酸测序、实时PCR、免疫组织化学和突变筛查等方法,评估三个患者队列(队列A - 56例、队列B - 100例、队列C - 76例)中MDS患者DNA修复基因(单链 - XPA、XPC、XPG、CSA、CSB和双链 - ATM、BRCA1、BRCA2、LIG4、RAD51)的甲基化和突变状态。结果显示,与高危MDS相比,低危MDS中XPA的甲基化程度更高。对于双链修复基因,ATM在转化为AML的患者中甲基化程度更高(p = 0.016)。与对照组相比,MDS中ATM基因表达下调(p = 0.042)。根据世界卫生组织2022年指南对患者进行分类时,ATM表达从低危亚型(如低增生性MDS)到高危MDS和AML逐渐降低。转化为AML的患者与未转化者相比,5mC/5hmC比值更高(p = 0.045)。此外,细胞遗传学风险差的患者组织甲基化评分高于风险好的患者(p = 0.035)。使用cBioPortal平台分析确定ATM是最常发生突变的DNA修复基因,存在多种突变,如移码突变和错义突变,其中大多数被归类为致癌突变。研究结果表明,ATM在MDS中常因甲基化或突变而沉默或下调,促进了向AML的进展。这突出了ATM在疾病进展中的潜在作用以及作为未来治疗策略靶点的潜力。